A

Arctic Bioscience AS
OSE:ABS

Watchlist Manager
Arctic Bioscience AS
OSE:ABS
Watchlist
Price: 3.36 NOK -0.3%
Market Cap: 90.2m NOK

Net Margin

-98.6%
Current
Improving
by 18%
vs 3-y average of -116.6%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-98.6%
=
Net Income
kr-43.4m
/
Revenue
kr44m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-98.6%
=
Net Income
kr-43.4m
/
Revenue
kr44m

Peer Comparison

Country Company Market Cap Net
Margin
NO
Arctic Bioscience AS
OSE:ABS
90.2m NOK
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
382B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
160.4B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.9B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.4B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.6B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.2B USD
Loading...
No Stocks Found

Market Distribution

Lower than 86% of companies in Norway
Percentile
14th
Based on 970 companies
14th percentile
-98.6%
Low
-4 257 300% — -4.2%
Typical Range
-4.2% — 6.7%
High
6.7% — 82 378.7%
Distribution Statistics
Norway
Min -4 257 300%
30th Percentile -4.2%
Median 0.8%
70th Percentile 6.7%
Max 82 378.7%

Arctic Bioscience AS
Glance View

Market Cap
90.2m NOK
Industry
Biotechnology

Arctic Bioscience AS engages in the development, manufacturing, and marketing of marine ingredients extracted from herring roe. The company is headquartered in Orsta, More Og Romsdal. The company went IPO on 2021-02-24. Arctic Bioscience’s purpose is to provide people with autoimmune disorders an effective and healthy therapy based on marine membrane lipids. The firm is developing HRO350 - a novel investigational drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. The firm's product portfolio includes, among others, Romega, which is a producer of an omega-3 dietary supplement made from herring roe in a form of a capsule, as well as herring caviar oil and herring caviar protein offered to Business-to-Business (B2B) customers. Arctic Bioscience AS has three subsidiaries Arctic Nutrition AS, Romega AS and Arctic Biopharma AS.

ABS Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-98.6%
=
Net Income
kr-43.4m
/
Revenue
kr44m
What is Arctic Bioscience AS's current Net Margin?

The current Net Margin for Arctic Bioscience AS is -98.6%, which is above its 3-year median of -116.6%.

How has Net Margin changed over time?

Over the last 3 years, Arctic Bioscience AS’s Net Margin has increased from -151.6% to -98.6%. During this period, it reached a low of -154.4% on Jun 30, 2024 and a high of -98.6% on Jul 30, 2025.

Back to Top